$SAVA
-
Markets
Cassava Sciences Alzheimer’s Drug Development After Phase 3 Setbacks
$SAVA Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company, has announced the discontinuation of its Alzheimer’s disease program following…
Read More » -
Markets
Cassava Sciences Advances Alzheimer’s Treatment with Promising Clinical Trials and Robust Financial Growth
$SAVA Cassava Sciences, Inc. (NASDAQ:SAVA) stands out in the biotechnology sector, focusing on developing treatments for neurodegenerative diseases, particularly Alzheimer’s…
Read More »